Galectin Therapeutics (GALT) director Eldred Kary adds 300 shares

Rhea-AI Filing Summary

Galectin Therapeutics director Eldred Kary reported a small open‑market purchase of company stock. On 02/06/2026, Kary bought 300 shares of common stock at $2.70 per share, bringing his direct holdings to 65,682 shares.

The filing also lists 2,425 shares held as custodian for a minor child under the Uniform Transfers to Minors Act and 2,000 shares held in a special needs trust where he serves as trustee. Kary disclaims beneficial ownership of these indirect holdings.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ELDRED KARY

(Last) (First) (Middle)

C/O GALECTIN THERAPEUTICS INC.

4960 PEACHTREE INDUSTRIAL BLVD., STE 240

(Street)

NORCROSS GA 30071

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/06/2026		P		300	A	$2.7	65,682	D
Common Stock								2,425	I	as UTMA custodian for a minor child(1)
Common Stock								2,000	I	held in trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose.

2. These shares are held in a special needs trust for which the Reporting Person serves as a trustee. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

	Jack W. Callicutt, by power of attorney	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Eldred Kary report at Galectin Therapeutics (GALT)?

Eldred Kary reported buying 300 Galectin Therapeutics common shares at $2.70 each. This open‑market purchase on February 6, 2026 increased his directly held stake to 65,682 shares, according to the Form 4 insider trading report.

How many Galectin Therapeutics shares does Eldred Kary now own directly?

After the reported transaction, Eldred Kary directly owns 65,682 Galectin Therapeutics common shares. This total reflects his February 6, 2026 purchase of 300 shares at $2.70 reported in the Form 4 filing with the SEC.

Were there any indirect Galectin Therapeutics holdings disclosed for Eldred Kary?

Yes. The Form 4 lists 2,425 Galectin shares held as UTMA custodian for a minor child and 2,000 shares in a special needs trust. Kary disclaims beneficial ownership of both indirect positions, despite being custodian and trustee respectively.

What does it mean that Eldred Kary disclaims beneficial ownership of some GALT shares?

Disclaiming beneficial ownership means Kary states he should not be treated as the true economic owner of those shares. In this filing, he disclaims ownership of shares held as UTMA custodian and in a special needs trust where he serves as trustee.

What was the purchase price in Eldred Kary’s Galectin Therapeutics trade?

The reported purchase price was $2.70 per Galectin Therapeutics common share. On February 6, 2026, Eldred Kary acquired 300 shares at this price, as disclosed in his Form 4 insider transaction report filed under Section 16 rules.